Use of bupropion in patients with depression and the associated risk of seizures: safety
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001182
Authors' recommendations: The available evidence of an increased risk of seizures in patients treated with bupropion for depression was inconclusive. This evidence was, however, limited to uncontrolled studies rated as low quality by the authors of the AHRQ systematic review.The absence of data from controlled trials may be a consideration when deciding on the criteria for use of bupropion in patients with depression.
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Antidepressive Agents, Second-Generation
- Risk Factors
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.